Presentation is loading. Please wait.

Presentation is loading. Please wait.

Opioid Dependence: Highlighting Buprenorphine Treatment Tony Tommasello, Pharmacist, PhD Associate Professor UM School of Pharmacy Office of Substance.

Similar presentations

Presentation on theme: "Opioid Dependence: Highlighting Buprenorphine Treatment Tony Tommasello, Pharmacist, PhD Associate Professor UM School of Pharmacy Office of Substance."— Presentation transcript:

1 Opioid Dependence: Highlighting Buprenorphine Treatment Tony Tommasello, Pharmacist, PhD Associate Professor UM School of Pharmacy Office of Substance Abuse Studies 515 West Lombard Street – 263 410 706-7513 ACPE Universal Program Number 025-999-06-054-X01

2 2 Learning Objectives At the conclusion of this program participants will be better able to: 1. Describe the forces that are driving the current increase in opioid abuse in the U.S. 2. Explain the need for non-pharmacological interventions for addicted patients 3. List therapeutic outcomes for addiction treatment 4. Distinguish medical withdrawal and medical maintenance 5. Explain the pharmacological basis for medical maintenance 6. Describe differences between methadone, buprenorphine, and naltrexone pharmacotherapy 7. List policy changes relative to opioid addiction treatment in America

3 3 Dynamics of a Heroin Epidemic Input  Demand reduction  Supply reduction Negative forces  2.4 million users  0.5 to 1 million addicts  150 to 200,000 new users each year  Broad-based screening  Addiction Severity Index  Treatment on demand  High heroin purity  Increased youth experimentation  Prescription opioid diversion Positive forces Narcotic Addiction Input Recovery

4 4 Number of US Narcotic Analgesic-Related ED Visits, 1994-2001 Source:

5 5 Teen Abuse of Rx Drugs: National Figures Curran JJ. Prescription for Disaster – The growing problem of prescription drug abuse in Maryland. September 2005.

6 6 Access to Treatment Is Limited Of the estimated 810,000 opioid-dependent persons in the United States, only 170,000 maintenance treatment slots exist

7 7 Aspects of Addiction Chronic Incurable but manageable Primary Not relieved by treating a suspected causative condition Progressive Gets worse if untreated Relapsing Prone to recurrence if untreated Fatal Premature death in untreated individuals

8 8

9 9 The Memory of Drugs

10 10 Opioid Addiction: Effects on the Body Opioids activate receptors in the central nervous system (CNS) and the gastrointestinal (GI) track CNS stimulation provides pleasurable feelings while GI stimulation produces constipation Other CNS effects include miosis, respiratory depression, drop in blood pressure

11 11 Why Treatment? Dysfunctional lifestyle of opioid addiction makes treatment a desired alternative Oral methadone and buprenorphine sublingual tablets are approved for both medical withdrawal and medical maintenance Rewards Negative Consequences Utility Theory

12 12 Addiction Treatment Optimal treatment combines pharmacological and nonpharmacological therapies for successful management of those addictions for which pharmacotherapy has been approved (opioid, alcohol, nicotine)

13 13 Primary Treatments Are Nonpharmacological Individual and/or group cognitive behavioral therapy Urine monitoring for drugs of abuse (also sweat, saliva, and blood) Support group participation – Narcotics Anonymous – Alcoholics Anonymous

14 14 Patient Response to Addiction Treatment Will Vary Patient characteristics—age, employment experiences, concurrent illnesses, family support Patient history—past treatment experiences, duration and level of drug use Patient motivation Length of time in treatment

15 15 Opioid Addiction Pharmacotherapy Enhances Treatment Outcomes Medical Withdrawal: Remove the opioid from the body and remain free of future opioid use Maintenance Therapy: Use a substitute opioid (agonist), “satisfy narcotic hunger,” eliminate craving Buprenorphine approved for both approaches

16 16 Pharmacology of Opioids Affinity: The strength with which a drug binds to its receptor Dissociation: The speed at which a drug uncouples from its receptor Efficacy: The percent of maximal response that a drug generates when it binds to the receptor

17 17 Full Agonists Bind to and activate receptor site As dose is increased, effect is increased until a maximum response is attained Examples: – Heroin – Oxycodone – Methadone

18 18 Antagonists Bind to the receptor without causing activity An antagonist can block the receptor from being activated by partial or full agonist Examples: – Naloxone – Naltrexone

19 19 Partial Agonists Bind to receptor and excite the receptor Activity reaches a plateau at which an increase in dose does not result in increased activity Examples: – Buprenorphine (also a kappa antagonist) – Pentazocine

20 20 Comparative Efficacies Full Agonist (Methadone) Partial Agonist (Buprenorphine) Antagonist (Naloxone) Conceptual Representation of Opioid Effect Versus Log Dose for Opioid Full Agonists, Partial Agonists, and Antagonists

21 21 Pharmacokinetic Distinctions Methadone Slowly absorbed from the gut reaching peak blood level in 45 to 90 minutes Half-life in maintenance patient is 24 hours Allows once-daily dosing Buprenorphine Sublingual tablets must be held under the tongue for 4 to 8 minutes for absorption Peak blood level in 60 minutes Half-life is 32 hours Allows once-daily or every-other-day dosing Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 2003;70(suppl 2):S39-S47.

22 22 Other Distinctions Buprenorphine has greater opioid receptor affinity and slower receptor dissociation than methadone Buprenorphine will displace a full agonist (methadone) and dock at the receptor, thus blocking other full agonists from attaching there Patients switching from methadone to buprenorphine may experience withdrawal distress and are advised to complete a reduction process before starting buprenorphine

23 23 Buprenorphine/Naloxone Combination and Buprenorphine Alone Two dosages: – Buprenorphine 2 mg with naloxone 0.5 mg – Buprenorphine 8 mg with naloxone 2 mg Two dosages: – Buprenorphine 2 mg – Buprenorphine 8 mg Tablet(s) should be held under the tongue until completely dissolved. SUBOXONE ® SUBUTEX ®

24 24 Medical Withdrawal With Buprenorphine Opioid-dependent individuals are treated with the goal of achieving a smooth transition to being substance free in a short period of time Dose-tapering patients should be engaged in counseling and have counseling continued after medical withdrawal is complete MDs and pharmacists should continue to reinforce to patients the importance of counseling after withdrawal

25 25 Induction Dosing Guidelines: Buprenorphine for Non-Methadone Patients Give the first dose after discontinuing opioids and some withdrawal symptoms are evident Precipitated withdrawal is avoided by giving the first dose of buprenorphine after withdrawal symptoms are displayed

26 26 Titrate to Stability Intoxication Withdrawal Insufficient Opioid Withdrawal Stabilization Intoxication Withdrawal Excessive Opioid

27 27 Staging and Grading Systems of Opioid Withdrawal (TIP 40) StageGradePhysical Signs/Symptoms Early Withdrawal (8–24 hours after last use) Grade 1 Lacrimation and/or rhinorrhea Diaphoresis Yawning, restlessness, insomnia Grade 2 Dilated pupils Piloerection Muscle twitching, myalgia and arthralgia Abdominal pain Fully Developed Withdrawal (1–3 days after last use) Grade 3 Tachycardia, tachypnea Hypertension Fever Anorexia or nausea Extreme restlessness Grade 4 Diarrhea and/or vomiting Dehydration Hyperglycemia Hypotension Curled-up (fetal) position

28 28 Signs of Opioid Intoxication and Overdose (TIP 40) Opioid Intoxication – Conscious – Sedated, drowsy – Slurred speech – “Nodding” or intermittently dozing – Memory impairment – Mood normal to euphoric – Pupillary constriction Opioid Overdose – Unconscious – Pinpoint pupils – Slow, shallow respirations; respirations below 10 per minute – Pulse rate below 40 per minute – Overdose triad: apnea, coma, pinpoint pupils (with terminal anoxia: fixed and dilated pupils)

29 29 Medical Withdrawal Dosing: Buprenorphine for Non-Methadone Patients A maximum dose of 8 mg can be administered on the first day as Subutex ® or as Suboxone ® Patients who still have withdrawal distress should be treated symptomatically and have their doses increased to a maximum of 16 mg for Day 2 Stabilize for 2 days before tapering, then taper 2 mg/day every 2 to 3 days

30 30 Model: Prescription Medical Withdrawal Ralph Amado, M.D. 3862 North Hampton Lane Rudolph, PA 38216 AA620395 XA620395 Roger Bacon 1063 Eastlight Dr. Essex, PA 38604 Physician name, address, DEA and waiver number Patient name and address Suboxone 2/0.5; Tablets #42 (forty-two) Drug name and strength Dosage form and quantity Day of tx 3*45678910111213 date5/255/265/275/285/295/305/316/16/26/36/4 # tabs 87654332211 SIG: for opioid withdrawal Date issued: 5/24/03 Patient: * Treatment on days 1 and 2 were done in the physician’s office Refill x 0 (zero) Physician signature: Ralph Amado

31 31 Medical Withdrawal “Withdrawal services are essentially acute services with short-term outcomes, whereas heroin dependence is a chronic relapsing condition, and positive long-term outcomes are more often associated with longer participation in treatment.” Vorrath E (ed) (2001) National Clinical Guidelines and Procedures for the use of Buprenorphine in the Treatment of Heroin Dependence (p.30). Available at

32 32 Medical Withdrawal Overemphasis on the importance of being drug free Underestimates the challenges associated with addiction Nonpharmacological interventions are critical to recovery success

33 33 Sustaining Abstinence Naltrexone (Trexan) 50 mg/day is used to prevent opioid effects if a patient uses opioids during recovery – Patient must be narcotic free 7 to 10 days before starting therapy – Naltrexone “blocks” heroin high and other effects – Noncompliance and low patient acceptance

34 34 Maintenance Treatment Patients consume a long-acting prescription opioid medication as a substitute for the illegal short-acting street opioid “The most dramatic effect of this treatment has been the disappearance of narcotic hunger” Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction. JAMA. 1965;193:646-650.

35 35 Outcomes of Treatment Methadone is the standard pharmacotherapy for opioid addiction Two outcomes for treatment – Reduction of illicit opioid abuse – Retention in treatment Medical maintenance is the best treatment option in achieving these outcomes

36 36 Buprenorphine Trials Data (Retention)

37 37 Buprenorphine Trials Data (Opioid Abuse)

38 38 Buprenorphine Trials Data (Urine Tests)

39 39 Strain EC et al. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and Addiction Severity Index. J Clin Psychopharmacol. 1995;16:59-67. Methadone (n=43)Buprenorphine (n=43)

40 40 Fudala PJ et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349:949-958. Buprenorphine-naloxone Buprenorphine alone Placebo

41 41 *Data were unavailable for two of the subjects in each group. † P values are for the overall comparison among three groups. Fudala PJ et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349:949-958. Adverse Events Reported by at Least 5 Percent of the Subjects in Any Treatment Group During the Double-Blind Trial* Adverse Event Buprenorphine and Naloxone (n=107) Buprenorphine Alone (n=103) Placebo (n=107) P Value † No. of subjects (%) Headache39 (36.4)30 (29.1)24 (22.4)0.08 Withdrawal syndrome27 (25.2)19 (18.4)40 (37.4)0.008 Pain24 (22.4)19 (18.4)20 (18.7)0.74 Insomnia15 (14.0)22 (21.4)17 (15.9)0.37 Nausea16 (15.0)14 (13.6)12 (11.2)0.73 Sweating15 (14.0)13 (12.6)11 (10.3)0.70 Abdominal pain12 (11.2)12 (11.7)7 (6.5)0.37 Rhinitis5 (4.7)10 (9.7)14 (13.1)0.09 Diarrhea4 (3.7)5 (4.9)16 (15.0)0.005 Infection6 (5.6)12 (11.7)7 (6.5)0.24 Chills8 (7.5)8 (7.8)8 (7.5)1.0 Constipation13 (12.1)8 (7.8)3 (2.8)0.03 Back pain4 (3.7)8 (7.8)12 (11.2)0.12 Vasodilation or flushing10 (9.3)4 (3.9)7 (6.5)0.28 Vomiting8 (7.5)8 (7.8)5 (4.7)0.66 Weakness7 (6.5)5 (4.9)7 (6.5)0.87

42 42 Model Prescription Maintenance Treatment Ralph Amado, M.D. 3862 North Hampton Lane Rudolph, PA 38216 AA620395 XA620395 Roger Bacon 1063 Eastlight Dr. Essex, PA 38604 Physician name, address, DEA and waiver number Patient name and address Suboxone 8/2 Tablets #60 (sixty) Drug name and strength Dosage form and quantity SIG: for opioid maintenance take two tablets daily dissolved under the tongue. Date issued: 5/24/03 Patient: Refill x 5 (five) Physician signature: Ralph Amado

43 43 Clinical Trials Dosing Sublingual buprenorphine daily doses of 8 to16 mg has been shown to be equally effective to oral methadone daily doses of 80 to 120 mg Buprenorphine maintenance is ideal for people abusing illegal opiates and for those who want to switch from methadone to buprenorphine Protocols for treatment can be found in the manual Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction: a Treatment Improvement Protocol (TIP) 40. Available at:

44 44 Drug Interactions Benzodiazepines—respiratory depression and cardiovascular collapse are possible when high doses are taken of both drugs. Patients must be closely monitored Other depressants produce additive effects on the CNS and may create interactive effects for patients operating motor vehicles or heavy machinery Buprenorphine given to tolerant physically dependent opiate addicts may produce withdrawal symptoms Buprenorphine is metabolized by the cytochrome p450 3A4 pathway. Drugs metabolized by the same pathway could result in higher than normal levels of either drug. Patients who are on both buprenorphine and one of these drugs need to be monitored closely

45 45 DATA (Drug Addiction Treatment Act) New Policy—New Practice The Children’s Health Act of 2000

46 46 Provisions of DATA An amendment to the Controlled Substances Act Allows certain physicians to prescribe and dispense for up to 30 patients Schedule III, IV, and V narcotic drugs that have been approved by the Food and Drug Administration for use in maintenance or detoxification treatment An authorized physician, one year after his or her initial notification, may petition to increase up to 100 the number of patients s/he will treat* * Changed by public law 109-56 on 8-2-2005

47 47 Authorized Buprenorphine Prescribers in the United States Physician locator selection provides map. Click on your state for physician listing

48 48 List of Drugs Approved by FDA for Use Under DATA Only buprenorphine formulated for sublingual use has been approved Approved on October 8, 2002 Two formulations, Subutex ® and Suboxone ® are available No other medications are approved for use under DATA

49 49 Expanded Access to Care One public health goal is to make opioid addiction treatment available on demand Methadone treatment clinics are operating at full capacity The Drug Addiction Treatment Act, if widely implemented, will offer numerous points of entry into opioid addiction treatment

50 50 Pharmacists’ Roles Case finding through screening Dispense buprenorphine sublingual tablets in accordance with the law Patient education on proper sublingual use Counsel patients regarding drug interactions Advise counseling interventions and help patients locate appropriate therapists Manage refill regularity

51 51 Code of Federal Regulation Title 42 Part 2 Protects the confidentiality of alcohol and drug abuse patients and their medical records Is different from HIPAA Restricts disclosure of patient information and any patient identifying information Requires consent for ANY information to be disclosed

52 52 Practice Implications Pharmacists need to practice diligence when counseling patients Pharmacists need to train their staff on the importance of not disclosing information on a patient receiving treatment Pharmacists must limit the information they provide to others

53 53 Initial Reports Are Favorable* Pharmacists involved in early trials with buprenorphine sublingual pharmacotherapy generally found the experience to be clinically rewarding Few expressed concerns about dangers associated with this treatment of opioid addiction * Raisch DW et al. J Am Pharm Assoc. 2005;45:23-32.

54 54 Summary Buprenorphine– effective pharmacotherapy for opioid addiction Knowledgeable pharmacists can effectively counsel patients undergoing treatment with this medication Pharmacists will be increasingly expected to dispense buprenorphine prescriptions and provide associated services

55 Opioid Dependence: Highlighting Buprenorphine Treatment Tony Tommasello, Pharmacist, PhD Associate Professor UM School of Pharmacy Office of Substance Abuse Studies 515 West Lombard Street – 263 410 706-7513

Download ppt "Opioid Dependence: Highlighting Buprenorphine Treatment Tony Tommasello, Pharmacist, PhD Associate Professor UM School of Pharmacy Office of Substance."

Similar presentations

Ads by Google